349 related articles for article (PubMed ID: 15802276)
1. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
3. Management of bone metastases in breast cancer.
Lipton A
Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapy in the oncology setting.
Lipton A
Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates: clinical experience.
Coleman RE
Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
15. [Bisphosphonates in adjuvant therapy of breast cancer].
Deuber HJ; Theiss F
Med Klin (Munich); 2010 Sep; 105(9):635-46. PubMed ID: 20878301
[TBL] [Abstract][Full Text] [Related]
16. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Harvey HA
Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Major PP; Cook R
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
[TBL] [Abstract][Full Text] [Related]
18. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in the treatment of skeletal metastases.
Conte P; Coleman R
Semin Oncol; 2004 Oct; 31(5 Suppl 10):59-63. PubMed ID: 15490377
[TBL] [Abstract][Full Text] [Related]
20. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
